Table 9.
Change in hepatic fat in individual studies
| Study | Parameter | Group | Baseline | Study completion | P value | P value between groups |
| Kuchay et al[11] | MRI-PDFF | Empagliflozin | 16.2 (7) | 11.3 (5.3) | < 0.0001 | < 0.0001 |
| Control | 16.4 (7.3) | 15.5 (6.7) | 0.054 | |||
| Ito et al[12] | L/S ratio | Ipragliflozin | 0.8 (0.2) | 1.0 (0.2) | < 0.05 | 0.90 |
| Pioglitazone | 0.8 (0.3) | 1.0 (0.2) | < 0.05 | |||
| Shibuya et al[13] | L/S ratio | Luseogliflozin | 0.9 (0.6-1.0) | 1.0 (0.8-1.2) | 0.0008 | 0.00002 |
| Metformin | 1.0 (0.8-1.1) | 0.9 (0.7-1.0) | 0.017 | |||
| Eriksson et al[14] | MRI-PDFF | Placebo | 15.1 (6.5) | -0.6 (1.9)1 | - | - |
| Omega-3 CA | 22.2 (11.0) | -3.2 (2.9)1 | - | Non-significant2 | ||
| Dapagliflozin | 17.3 (9.1) | -2.2 (3.3)1 | - | Non-significant2 | ||
| O + D | 17.8 (9.2) | -3.2 (3.5)1 | - | < 0.052 | ||
| Sumida et al[18] | MRI-HFF | Luseogliflozin | 21.5 (7.2) | 15.7 (6.8) | < 0.001 | - |
1
Change from baseline.
2
Compared to placebo.
MRI-PDFF: Magnetic resonance imaging-derived proton density fat fraction; L/S ratio: Liver/spleen attenuation ratio; MRI-HFF: Magnetic resonance imaging-hepatic fat fraction; CA: Carboxylic acid; O + D: Omega-3 CA + Dapagliflozin.